[go: up one dir, main page]

PE20091557A1 - Derivados de piridazina y su uso como agentes terapeuticos - Google Patents

Derivados de piridazina y su uso como agentes terapeuticos

Info

Publication number
PE20091557A1
PE20091557A1 PE2009000280A PE2009000280A PE20091557A1 PE 20091557 A1 PE20091557 A1 PE 20091557A1 PE 2009000280 A PE2009000280 A PE 2009000280A PE 2009000280 A PE2009000280 A PE 2009000280A PE 20091557 A1 PE20091557 A1 PE 20091557A1
Authority
PE
Peru
Prior art keywords
alkyl
pyridazin
piperazin
therapeutic agents
compounds
Prior art date
Application number
PE2009000280A
Other languages
English (en)
Inventor
Andreas Billich
Michael D Winther
Yigal Paul Goldberg
Gesine Winzenburg
Andreas Fritze
Karin Rapp
Original Assignee
Xenon Pharmaceuticals Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39970096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc, Novartis Ag filed Critical Xenon Pharmaceuticals Inc
Publication of PE20091557A1 publication Critical patent/PE20091557A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE PIRIDAZINA FORMULA (I) DONDE x E y SON CADA UNO 1-3; W ES -C(O)N(R1)-, -C(O)N[C(O)R1a]-, N(R1)C(O)N(R1), ENTRE OTROS; R1 ES H, ALQUILO C1-C6, ENTRE OTROS; R1a ES H, ALQUILO C1-C6, CICLOALQUILO; V ES -C(O)-, -C(S)-, -C(R10)H; R2 ES ALQUILO C1-C12, ALQUENILO C2-C12, HIDROXIALQUILO C2-C12, ENTRE OTROS; R3 ES ALQUILO C1-C12, ALCOXI C1-C12, ALCOXIALQUILO C2-12, ENTRE OTROS; R4 Y R5 SON CADA UNO H, HALO, -CH3, ENTRE OTROS; R6, R6a, R7, R7a, R8, R8a, R9 Y R9a SON CADA UNO H, ALQUILO C1-C3, ENTRE OTROS. SON COMPUESTOS SELECCIONADOS: {6-[4-(2-TRIFLUOROMETILBENZOIL)-PIPERAZIN-1-IL]PIRIDAZIN-3-IL}AMIDA DEL ACIDO 4-METILPENTANOICO; 2-BENCILOXI-N-{6-[4-(2-TRIFLUOROMETILBENZOIL)PIPERAZIN-1-IL]-PIRIDAZIN-3-IL}ACETAMIDA; 4-CICLOHEXIL-N-{6-[4-(2-TRIFLUOROMETILBENZOIL)PIPERAZIN-1-IL]-PIRIDAZIN-3-IL}BUTIRAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE DESATURASA DE ESTEAROIL-CoA, UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DE LA PIEL TALES COMO ACNE, ROSACEA, PIEL SEBORREICA, ENTRE OTROS
PE2009000280A 2008-02-25 2009-02-25 Derivados de piridazina y su uso como agentes terapeuticos PE20091557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/036,685 US7759348B2 (en) 2003-07-30 2008-02-25 Pyridazine derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
PE20091557A1 true PE20091557A1 (es) 2009-10-30

Family

ID=39970096

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000280A PE20091557A1 (es) 2008-02-25 2009-02-25 Derivados de piridazina y su uso como agentes terapeuticos

Country Status (15)

Country Link
US (3) US7759348B2 (es)
EP (1) EP2257291A2 (es)
JP (1) JP2011513296A (es)
KR (1) KR20100126434A (es)
CN (1) CN101980709A (es)
AR (1) AR070852A1 (es)
AU (1) AU2009219809A1 (es)
BR (1) BRPI0908225A2 (es)
CA (1) CA2716336A1 (es)
CL (1) CL2009000422A1 (es)
MX (1) MX2010009206A (es)
PE (1) PE20091557A1 (es)
RU (1) RU2010139285A (es)
TW (1) TW200940060A (es)
WO (1) WO2009106991A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1887875B (zh) * 2005-06-30 2011-04-06 深圳市东阳光实业发展有限公司 哒嗪胺衍生物及其用于制备小rna病毒抑制剂的用途
TWI362930B (en) 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
EP2236505A1 (de) * 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
FR2948939B1 (fr) 2009-08-05 2013-03-22 Pf Medicament Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
FR2950807B1 (fr) * 2009-10-06 2012-02-03 Lvmh Rech Composition cosmetique contenant des liposomes encapsules dans un compose oxazolidin-2-one
FR2958935B1 (fr) 2010-04-19 2012-06-22 Pf Medicament Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
JP2014502510A (ja) * 2010-12-31 2014-02-03 ゼウス サイエンティフィック、インク． 分子核酸ベースの技術を使用している細胞生存度を決定する改良された方法
KR101589837B1 (ko) 2011-06-22 2016-01-29 퍼듀 퍼머 엘피 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도
US9233102B2 (en) 2012-03-07 2016-01-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2016527307A (ja) * 2013-08-08 2016-09-08 ガルデルム セラピューティクス リミテッド 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物
WO2015200674A1 (en) * 2014-06-25 2015-12-30 The General Hospital Corporation Neuroactive compounds and methods of using the same
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
JP6905530B2 (ja) 2015-09-16 2021-07-21 メタクリン，インク． ファルネソイドｘ受容体アゴニストとその使用
JP6583126B2 (ja) * 2016-04-28 2019-10-02 信越化学工業株式会社 新規カルボン酸オニウム塩、化学増幅レジスト組成物、及びパターン形成方法
WO2017223474A1 (en) 2016-06-23 2017-12-28 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
ES3025460T3 (en) 2017-01-06 2025-06-09 Janssen Pharmaceutica Nv Scd inhibitor for the treatment of neurological disorders
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
SG11201908330PA (en) 2017-03-15 2019-10-30 Metacrine Inc Farnesoid x receptor agonists and uses thereof
US11018285B2 (en) 2017-03-23 2021-05-25 Seoul Semiconductor Co., Ltd. Display device and manufacturing method thereof
US10821075B1 (en) * 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020012875A2 (pt) * 2017-12-27 2021-01-05 St. Jude Children¿S Research Hospital, Inc. Moduladores de pequenas moléculas das pantotenato quinases
CN111787939B (zh) 2017-12-27 2024-09-13 圣朱德儿童研究医院有限公司 治疗castor相关疾病的方法
WO2019158572A1 (en) * 2018-02-15 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
EP3768269B1 (en) 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Compounds and uses thereof
HRP20251321T1 (hr) 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2020198526A2 (en) 2019-03-27 2020-10-01 St. Jude Children's Research Hospital Small molecule modulators of pank
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
AU2021239956A1 (en) 2020-03-18 2022-10-13 Eli Lilly And Company Formulations of a farnesoid X receptor agonist
EP4555995A1 (fr) * 2023-11-14 2025-05-21 Laboratoires d'Anjou Utilisation d'un acide gras cyclopropénique pour inhiber l'activité de la scd

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
WO2000009754A2 (en) 1998-08-14 2000-02-24 Johnson & Johnson Consumer Companies, Inc. HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
CA2339748A1 (en) * 1998-08-14 2000-02-24 Johnson & Johnson Consumer Companies, Inc. Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
JP3637961B2 (ja) 1999-09-16 2005-04-13 田辺製薬株式会社 芳香族含窒素六員環化合物
CA2398940C (en) 2000-02-24 2012-02-21 Xenon Genetics, Inc. Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
DE60130771T2 (de) 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
EP1389189A2 (en) 2001-05-22 2004-02-18 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
ES2316575T3 (es) 2001-06-15 2009-04-16 Astellas Pharma Inc. Derivado de fenilpiridincarbonilpiperazina.
MXPA04007775A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7330129B2 (en) * 2003-07-16 2008-02-12 Black & Decker Inc. System and method for data retrieval in AC power tools via an AC line cord
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
CA2533897A1 (en) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
PT1651620E (pt) 2003-07-30 2012-02-10 Xenon Pharmaceuticals Inc Derivados de piperizina e sua utilização como agentes terapêuticos
EP2316827B1 (en) * 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2008003753A1 (en) * 2006-07-07 2008-01-10 Biovitrum Ab (Publ) Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity

Also Published As

Publication number Publication date
JP2011513296A (ja) 2011-04-28
TW200940060A (en) 2009-10-01
CN101980709A (zh) 2011-02-23
AR070852A1 (es) 2010-05-12
EP2257291A2 (en) 2010-12-08
CA2716336A1 (en) 2009-09-03
WO2009106991A3 (en) 2009-11-05
WO2009106991A2 (en) 2009-09-03
US20100311763A1 (en) 2010-12-09
CL2009000422A1 (es) 2010-09-21
RU2010139285A (ru) 2012-04-10
MX2010009206A (es) 2010-11-10
US20110021530A1 (en) 2011-01-27
US7964591B2 (en) 2011-06-21
KR20100126434A (ko) 2010-12-01
BRPI0908225A2 (pt) 2016-11-01
US20080280916A1 (en) 2008-11-13
US7759348B2 (en) 2010-07-20
AU2009219809A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
PE20091557A1 (es) Derivados de piridazina y su uso como agentes terapeuticos
CR20110617A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
MX383688B (es) Derivados de piridona amida como agonistas de canales de sodio nav1. 8 y el uso de los mismos en el tratamiento de dolor.
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
EA201170922A1 (ru) Производные сульфонамида
PE20071095A1 (es) Derivados policiclicos de indazol como inhibidores de erk
IN2012DN01325A (es)
PE20090770A1 (es) Derivados de benzoxazolona
AR077765A1 (es) Inhibidores de los virus flaviviridae
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20120780A1 (es) Nicotinamida sustituida como moduladores kcnq2/3
CR20110616A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20061065A1 (es) Derivados de piridazina como agentes inhibidores de esteaoril-coa desaturasa
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
GEAP201813377A (en) New therapeutical composition containing apomorphine as active ingredient
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
HRP20201905T1 (hr) Inhibitori aldoza reduktaze i postupci njihove upotrebe

Legal Events

Date Code Title Description
FA Abandonment or withdrawal